Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-25-005829
Filing Date
2025-04-29
Accepted
2025-04-29 16:05:41
Documents
18
Period of Report
2025-06-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A ganx-20250624xdef14a.htm   iXBRL DEF 14A 732042
2 GRAPHIC ganx-20250624xdef14a_a001.jpg GRAPHIC 7845
3 GRAPHIC ganx-20250624xdef14a_bg001.jpg GRAPHIC 180333
4 GRAPHIC ganx-20250624xdef14a_bg002.jpg GRAPHIC 102206
  Complete submission text file 0001558370-25-005829.txt   1981809

Data Files

Seq Description Document Type Size
5 EX-101.SCH ganx-20250624.xsd EX-101.SCH 4632
6 EX-101.DEF ganx-20250624_def.xml EX-101.DEF 3557
7 EX-101.LAB ganx-20250624_lab.xml EX-101.LAB 6830
8 EX-101.PRE ganx-20250624_pre.xml EX-101.PRE 5065
20 EXTRACTED XBRL INSTANCE DOCUMENT ganx-20250624xdef14a_htm.xml XML 127224
Mailing Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814
Business Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814 (301) 500-1556
Gain Therapeutics, Inc. (Filer) CIK: 0001819411 (see all company filings)

EIN.: 851726310 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40237 | Film No.: 25887146
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)